A Phase 2 interventional study of telaprevir or matching placebo and telaprevir or matching placebo in Hepatitis C and HIV Infections, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 16 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-10-10.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing peginterferon alfa-2a in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C.
Among the 49 studies testing peginterferon alfa-2a in Hepatitis C, this one is the 26th largest by enrollment, is one of 4 that started in 2009, is one of 13 in phase 2, and was the 28th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 49 studies testing peginterferon alfa-2a in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 15 · Phase 3 16 · Phase 4 17
First in 2000; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 64 across the 49 interventional studies. Of the 49 that completed or were terminated, 18 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 49 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2009, is one of 7 in phase 2, and was the 12th registered.
Vertex Pharmaceuticals Incorporated’s Hepatitis C studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing peginterferon alfa-2a in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 19 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV and human immunodeficiency virus (HIV).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The dose of ribavirin used (fixed versus weight-based) is region dependent
Drug: telaprevir or matching placebo · Biological: peginterferon alfa-2a · Drug: ribavirin (fixed dose) · Drug: ribavirin (weight-based dose)
The dose of ribavirin used (fixed versus weight-based) is region dependent
Drug: telaprevir or matching placebo · Biological: peginterferon alfa-2a · Drug: ribavirin (fixed dose) · Drug: ribavirin (weight-based dose)
Tablet, Oral, 750 mg, q8h, 12 weeks
Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
Subcutaneous injection, 180 μg, once weekly, 48 weeks
Tablet, Oral, 800 mg, b.i.d., 48 weeks
Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
Proportion of Subjects Achieving Undetectable HCV RNA at Week 12
Time frame: 12 weeks after first dose of study drug
Proportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12
number of subjects with undetectable HCV RNA
Time frame: 4 and 12 weeks after the first dose of study drug
Proportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment
Time frame: 12 weeks after last dose of study drug
Effect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure
Time frame: through 12 weeks after first dose of study drug
Median Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)
Ctrough ratio of HAART medication with telaprevir (test) and without telaprevir (reference)
Time frame: through 12 weeks after first dose of study drug
Median Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)
Ctrough of HAART medication with telaprevir (test) and without telaprevir (reference)
Time frame: through 12 weeks after first dose of study drug
| Milestone | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 17 | 8 | 15 | 8 |
| Completed | 6 | 5 | 14 | 6 | 12 | 7 |
| Not completed | 1 | 2 | 3 | 2 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Unable to come to study follow-up visits | 0 | 1 | 0 | 0 | 0 | 0 |
| participants | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR |
|---|---|---|---|---|---|---|
| Proportion of Subjects Achieving Undetectable HCV RNA at Week 12 | 6 | 2 | 14 | 2 | 10 | 2 |
number of subjects with undetectable HCV RNA
| participants | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR |
|---|---|---|---|---|---|---|
| Week 4 (RVR) | 5 | 0 | 12 | 0 | 9 | 0 |
| Weeks 4 and 12 (eRVR) | 4 | 0 | 12 | 0 | 7 | 0 |
| participants | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR |
|---|---|---|---|---|---|---|
| SVR12 | 5 | 2 | 11 | 4 | 12 | 4 |
| SVR24 | 5 | 2 | 11 | 4 | 12 | 4 |
| ratio (test/reference) | EFV-based (Test, N=15) vs No HAART (Reference, N=7) | ATV/R-based (Test, N=13) vs No HAART (Reference, N=7) |
|---|---|---|
| Cmin | 0.8842 (0.5467 to 1.4300) | 1.3059 (0.7981 to 2.1367) |
| Cavg | 0.9610 (0.6615 to 1.3961) | 1.0930 (0.7456 to 1.6023) |
| Cmax | 1.0061 (0.7306 to 1.3855) | 1.0075 (0.7260 to 1.3982) |
Ctrough ratio of HAART medication with telaprevir (test) and without telaprevir (reference)
| ratio (test/reference) | T/PR | Pbo/PR |
|---|---|---|
| Efavirenz | 0.94 (0.42 to 2.84) | 0.79 (0.48 to 1.48) |
| Tenofovir | 1.06 (0.46 to 17.4) | 0.64 (0.30 to 2.01) |
Ctrough of HAART medication with telaprevir (test) and without telaprevir (reference)
| ratio (test/reference) | T/PR | Pbo/PR |
|---|---|---|
| Atazanavir (N=12 T/PR, N=6 Pbo/PR) | 1.16 (0.39 to 45.0) | 1.03 (0.49 to 2.05) |
| Tenofovir (N=13 T/PR, N=7 Pbo/PR) | 0.75 (0.28 to 40.7) | 0.93 (0.55 to 1.68) |
| Ritonavir (N=9 T/PR, N=7 Pbo/PR) | 0.72 (0.08 to 4.40) | 0.74 (0.21 to 4.20) |
Collected over first dose of study drug until 4 weeks after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T/PR | — | 7/38 (18.4%) | 38/38 (100%) |
| Total PR | — | 2/22 (9.1%) | 22/22 (100%) |
| Event | T/PR | Total PR |
|---|---|---|
| AppendicitisInfections and infestations | 0/38 | 1/22 |
| AnaemiaBlood and lymphatic system disorders | 0/38 | 1/22 |
| PeritonitisGastrointestinal disorders | 0/38 | 1/22 |
| Groin InfectionInfections and infestations | 1/38 | 0/22 |
| Pyelonephritis AcuteInfections and infestations | 1/38 | 0/22 |
| Cellulitis StaphylococcalInfections and infestations | 1/38 | 0/22 |
| Staphylococcal AbscessInfections and infestations | 1/38 | 0/22 |
| Staphylococcal InfectionInfections and infestations | 1/38 | 0/22 |
| Hemolytic AnemiaBlood and lymphatic system disorders | 1/38 | 0/22 |
| Acute Myocardial InfarctionCardiac disorders | 1/38 | 0/22 |
| Event | T/PR | Total PR |
|---|---|---|
| FatigueGeneral disorders | 16/38 | 9/22 |
| PruritusSkin and subcutaneous tissue disorders | 15/38 | 2/22 |
| HeadacheNervous system disorders | 14/38 | 6/22 |
| NauseaGastrointestinal disorders | 13/38 | 5/22 |
| DiarrhoeaGastrointestinal disorders | 9/38 | 4/22 |
| NeutropeniaBlood and lymphatic system disorders | 9/38 | 5/22 |
| InsomniaPsychiatric disorders | 5/38 | 5/22 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/38 | 5/22 |
| Weight DecreasedInvestigations | 5/38 | 5/22 |
| PyrexiaGeneral disorders | 8/38 | 2/22 |
All randomized subjects who received at least 1 dose of study drug
| Age Continuous(years) | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR | Total |
|---|---|---|---|---|---|---|---|
| median (min, max) | 39.4 (34 to 50) | 47.5 (42 to 65) | 47.5 (31 to 57) | 47.0 (31 to 53) | 52.0 (36 to 59) | 39.0 (26 to 53) | 44.5 (26 to 65) |
| Sex: Female, Male(Participants) | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 0 | 1 | 2 | 1 | 7 |
| Male | 6 | 4 | 16 | 7 | 13 | 7 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 | 1 | 3 | 3 | 17 |
| Not Hispanic or Latino | 4 | 4 | 10 | 7 | 12 | 5 | 42 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR | Total |
|---|---|---|---|---|---|---|---|
| White | 2 | 3 | 12 | 5 | 13 | 7 | 42 |
| Black/African American | 4 | 3 | 3 | 3 | 2 | 1 | 16 |
| American Indian/Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Part A: T/PR | Part A: Pbo/PR | Part B: EFV-based HAART + T/PR | Part B: EFV-based HAART + Pbo/PR | Part B: ATV/R-based HAART + T/PR | Part B: ATV/R-based HAART + Pbo/PR | Total |
|---|---|---|---|---|---|---|---|
| North America | 7 | 5 | 13 | 8 | 9 | 4 | 46 |
| United States | 7 | 5 | 13 | 8 | 9 | 4 | 46 |
| Europe | 0 | 1 | 3 | 0 | 6 | 4 | 14 |
| Germany | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| Spain | 0 | 1 | 2 | 0 | 3 | 3 | 9 |
| France | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
The record gives a start of Oct 2009 and a primary completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin
Vertex Pharmaceuticals Incorporated →